M. Arends, C. Wanner, D. Hughes, A. Mehta, D. Oder et al., Characterization of classical and nonclassical fabry disease: A multicenter study, J. Am. Soc. Nephrol, vol.28, pp.1631-1641, 2017.

P. J. Meikle, J. J. Hopwood, A. E. Clague, and W. F. Carey, Prevalence of lysosomal storage disorders, Jama, vol.281, pp.249-254, 1999.

T. Inoue, K. Hattori, K. Ihara, A. Ishii, K. Nakamura et al., Newborn screening for Fabry disease in Japan: Prevalence and genotypes of Fabry disease in a pilot study, J. Hum. Genet, vol.58, 2013.

T. P. Mechtler, S. Stary, T. F. Metz, V. R. De-jesús, S. Greber-platzer et al., Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria, Lancet, vol.379, pp.335-341, 2012.

M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan et al., High incidence of later-onset Fabry disease revealed by newborn screening, Am. J. Hum. Genet, vol.79, pp.31-40, 2006.

P. V. Hopkins, C. Campbell, T. Klug, S. Rogers, J. Raburn-miller et al., Lysosomal storage disorder screening implementation: Findings from the first six months of full population pilot testing in Missouri, J. Pediatrics, vol.166, pp.172-177, 2015.

H. Y. Lin, K. W. Chong, J. H. Hsu, H. C. Yu, C. C. Shih et al., High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population, Circ. Cardiovasc. Genet, vol.2, pp.450-456, 2009.

J. Kramer and F. Weidemann, Biomarkers for diagnosing and staging of Fabry disease, Curr. Med. Chem, vol.25, pp.1530-1537, 2018.

S. Waldek, M. R. Patel, M. Banikazemi, R. Lemay, and P. Lee, Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry, Genet. Med. Off. J. Am. Coll. Med Genet, vol.11, pp.790-796, 2009.

A. S. Thomas and A. B. Mehta, Difficulties and barriers in diagnosing Fabry disease: What can be learnt from the literature?, Expert Opin. Med. Diagn, vol.7, pp.589-599, 2013.

R. El-abassi, D. Singhal, and J. D. England, Fabry's disease, J. Neurol. Sci, vol.344, pp.5-19, 2014.

G. Duro, C. Zizzo, G. Cammarata, A. Burlina, A. Burlina et al., Mutations in the GLA Gene and LysoGb3: Is it really Anderson-Fabry disease?, Int. J. Mol. Sci, vol.19, 2018.

B. Winchester and E. Young, Biochemical and genetic diagnosis of Fabry disease, Fabry Disease: Perspectives from 5 Years of FOS, 2006.

R. J. Desnick, K. Y. Allen, S. J. Desnick, M. K. Raman, R. W. Bernlohr et al., Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes: ?-galactosidase activities in plasma, serum, urine, and leukocytes, J. Lab. Clin. Med, vol.81, pp.157-171, 1973.

N. Chamoles, M. Blanco, D. Gaggioli, and . Fabry-disease, Enzymatic diagnosis in dried blood spots on filter paper, Clin. Chim. Acta, vol.1, pp.195-196, 2001.

R. J. Desnick, Y. A. Ioannou, and C. M. Eng, A deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Disease, vol.3, pp.2741-2784, 2001.

K. Mills, A. Johnson, and B. Winchester, Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry, FEBS Lett, vol.515, pp.171-176, 2002.

A. Nowak, T. Mechtler, D. C. Kasper, and R. J. Desnick, Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease, Mol. Genet. Metab, vol.121, pp.320-324, 2017.

F. Boscaro, G. Pieraccini, G. L. Marca, G. Bartolucci, C. Luceri et al., Rapid quantitation of globotriaosylceramide in human plasma and urine: A potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease, Rapid Commun. Mass Spectrom, vol.16, pp.1507-1514, 2002.

J. M. Aerts, J. E. Groener, S. Kuiper, W. E. Donker-koopman, A. Strijland et al., Elevated globotriaosylsphingosine is a hallmark of Fabry disease, Proc. Natl. Acad. Sci, vol.105, pp.2812-2817, 2008.

A. Talbot, K. Nicholls, J. M. Fletcher, and M. Fuller, A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease, Mol. Genet. Metab, vol.122, pp.121-125, 2017.

Y. A. Zarate and R. J. Hopkin, Fabry's disease, Lancet, vol.372, pp.1427-1435, 2008.

C. Auray-blais, D. Cyr, K. Mills, R. Giguere, and R. Drouin, Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease, J. Inherit. Metab. Dis, vol.30, 2007.

A. Mehta, Fabry disease: A review of current enzyme replacement strategies. Expert Opin, Orphan Drugs, vol.3, pp.1319-1330, 2015.

R. Schiffmann, J. B. Kopp, H. A. Austin, S. Sabnis, D. F. Moore et al., Enzyme replacement therapy in Fabry disease: A randomized controlled trial, Jama, vol.285, pp.2743-2749, 2001.

E. H. Mccafferty, L. J. Scott, and . Migalastat, A review in Fabry disease, Drugs, vol.79, pp.543-554, 2019.

M. Arends, M. Biegstraaten, D. A. Hughes, A. Mehta, P. M. Elliott et al., Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors, PLoS ONE, vol.12, 2017.

V. Citro, M. Cammisa, L. Liguori, C. Cimmaruta, J. Lukas et al., The large phenotypic spectrum of Fabry disease requires graduated diagnosis and personalized therapy: A meta-analysis can help to differentiate missense mutations, Int. J. Mol. Sci, vol.17, 2010.

R. Reisin, A. Perrin, and P. Garcia-pavia, Time delays in the diagnosis and treatment of Fabry disease, Int. J. Clin. Pract, vol.71, 2017.

B. Sudrie-arnaud, F. Marguet, S. Patrier, J. Martinovic, F. Louillet et al., Metabolic causes of nonimmune hydrops fetalis: A next-generation sequencing panel as a first-line investigation, Clin. Chim. Acta Int. J. Clin. Chem, vol.481, pp.1-8, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02356382

A. Tebani, I. Schmitz-afonso, L. Abily-donval, B. Heron, M. Piraud et al., Urinary metabolic phenotyping of mucopolysaccharidosis type I combining untargeted and targeted strategies with data modeling, Clin. Chim. Acta Int. J. Clin. Chem, vol.475, pp.7-14, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02445369

A. Tebani, C. Afonso, S. Marret, and S. Bekri, Omics-based strategies in precision medicine: Toward a paradigm shift in inborn errors of metabolism investigations, Int. J. Mol. Sci, vol.17, 1555.
URL : https://hal.archives-ouvertes.fr/hal-02452350

A. Tebani, L. Abily-donval, C. Afonso, S. Marret, and S. Bekri, Clinical metabolomics: The new metabolic window for inborn errors of metabolism investigations in the post-genomic era, Int. J. Mol. Sci, vol.17, 1167.
URL : https://hal.archives-ouvertes.fr/hal-02453944

D. Cigna, C. D'anna, C. Zizzo, D. Francofonte, I. Sorrentino et al., Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: Preliminary findings, Mol. Biosyst, vol.9, pp.1162-1168, 2013.

H. Yogasundaram, A. Nikhanj, B. N. Putko, M. Boutin, S. Jain-ghai et al., Elevated inflammatory plasma biomarkers in patients with Fabry disease: A critical link to heart failure with preserved ejection fraction, J. Am. Heart Assoc, vol.7, 2018.

V. Matafora, M. Cuccurullo, A. Beneduci, O. Petrazzuolo, A. Simeone et al., Early markers of Fabry disease revealed by proteomics, Mol. Biosyst, vol.11, pp.1543-1551, 2015.

V. Manwaring, W. E. Heywood, R. Clayton, R. H. Lachmann, J. Keutzer et al., The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: Evidence of presymptomatic kidney disease in pediatric Fabry and Type-I diabetic patients, J. Proteome Res, vol.12, 2013.

S. H. Heo, E. Kang, Y. M. Kim, H. Go, K. Y. Kim et al., Fabry disease: Characterisation of the plasma proteome pre-and post-enzyme replacement therapy, J. Med Genet, vol.54, pp.771-780, 2017.

D. F. Moore, O. V. Krokhin, R. C. Beavis, M. Ries, C. Robinson et al., Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities, Proc. Natl. Acad. Sci, vol.104, pp.2873-2878, 2007.

M. J. Birket, S. Raibaud, M. Lettieri, A. D. Adamson, V. Letang et al., A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology, Stem Cell Rep, vol.13, pp.380-393, 2019.

H. Song, C. Chien, A. A. Yarmishyn, S. Chou, Y. Yang et al., Generation of GLA-knockout human embryonic stem cell lines to model autophagic dysfunction and exosome secretion in Fabry disease-associated hypertrophic cardiomyopathy, vol.8, p.327, 2019.

F. Weidemann, M. Beer, M. Kralewski, J. Siwy, and C. Kampmann, Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: Results from the SOPHIA study, Mol. Genet. Metab, vol.126, pp.169-182, 2019.

I. D. Doykov, W. E. Heywood, V. Nikolaenko, J. ?piewak, J. Hällqvist et al., Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease, J. Med. Genet, vol.57, pp.38-47, 2020.

W. Mauhin, O. Lidove, D. Amelin, F. Lamari, C. Caillaud et al., Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY, Orphanet J. Rare Dis, vol.13, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02086919

L. Eriksson, J. Trygg, and S. Wold, A chemometrics toolbox based on projections and latent variables, J. Chemom, vol.28, pp.332-346, 2014.

F. J. Alharbi, S. Baig, C. Auray-blais, M. Boutin, D. G. Ward et al., Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease, J. Inherit. Metab. Dis, vol.41, pp.239-247, 2018.

M. Murakami and M. Simons, Fibroblast growth factor regulation of neovascularization, Curr. Opin. Hematol, vol.15, pp.215-220, 2008.

M. H. Lee, E. N. Choi, Y. J. Jeon, and S. C. Jung, Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy, Int. J. Mol. Med, vol.30, pp.1275-1280, 2012.

Y. Cai, J. Zhang, X. Lao, H. Jiang, Y. Yu et al., Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer, Cancer Sci, vol.107, pp.1141-1150, 2016.

J. Hamamoto, H. Yasuda, Y. Nonaka, M. Fujiwara, Y. Nakamura et al., The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells, Biochem. Biophys. Res. Commun, vol.503, pp.1330-1334, 2018.

K. Satoh, Globotriaosylceramide induces endothelial dysfunction in fabry disease, Arterioscler. Thromb. Vasc. Biol, vol.34, 2014.

S. Bird, E. Hadjimichael, A. Mehta, U. Ramaswami, and D. Hughes, Fabry disease and incidence of cancer, Orphanet J. Rare Dis, vol.12, 2017.

B. L. Thurberg, D. P. Germain, F. Perretta, I. E. Jurca-simina, and J. M. Politei, Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies, Mol. Genet. Metab. Rep, vol.11, pp.75-80, 2017.

P. Rozenfeld and S. Feriozzi, Contribution of inflammatory pathways to Fabry disease pathogenesis, Mol. Genet. Metab, vol.122, pp.19-27, 2017.

M. C. Liebau, F. Braun, K. Höpker, C. Weitbrecht, V. Bartels et al., Dysregulated autophagy contributes to podocyte damage in Fabry's disease, PLoS ONE, vol.8, 2013.

M. Chévrier, N. Brakch, L. Céline, D. Genty, Y. Ramdani et al., Autophagosome maturation is impaired in Fabry disease, Autophagy, vol.6, pp.589-599, 2010.

K. H. Chen, Y. Chien, K. L. Wang, H. B. Leu, C. Y. Hsiao et al., Evaluation of proinflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy, Can. J. Cardiol, vol.32, p.1221, 2016.

C. J. Coats, V. Parisi, M. Ramos, K. Janagarajan, C. O'mahony et al., Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease, Am. J. Cardiol, vol.111, pp.111-117, 2013.

N. Seydelmann, D. Liu, J. Krämer, C. Drechsler, K. Hu et al., High-sensitivity troponin: A clinical blood biomarker for staging cardiomyopathy in Fabry disease, J. Am. Heart Assoc, vol.5, 2016.

K. Hu, D. Liu, T. Salinger, D. Oder, S. Knop et al., Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function, J. Thorac. Dis, vol.10, pp.4966-4975, 2018.

I. X. Mcleod, X. Zhou, Q. J. Li, F. Wang, and Y. W. He, The class III kinase Vps34 promotes T lymphocyte survival through regulating IL-7Ralpha surface expression, J. Immunol, vol.187, pp.5051-5061, 2011.

W. Lundstrom, N. M. Fewkes, and C. L. Mackall, IL-7 in human health and disease, Semin. Immunol, vol.24, pp.218-224, 2012.

F. Stappers, D. Scharnetzki, B. Schmitz, D. Manikowski, S. M. Brand et al., Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity, J. Inherit. Metab. Dis, vol.43, pp.334-347, 2020.